Scancell Holdings PLC
Company Profile
Business description
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.
Contact
Sanders Road
Unit 202, Bellhouse Building
Oxford Science Park
OxfordOX4 4GD
GBRT: +44 1865582066
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 April 2025
Employees
58
Stocks News & Analysis
stocks
16 ASX stocks to buy and hold forever, revisited
stocks
This ASX200 reject could be a contrarian buying opportunity
stocks
A 15 step checklist from Buffett's forgotten inspiration
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,973.10 | 130.30 | -1.61% |
| CAC 40 | 7,941.91 | 105.69 | -1.31% |
| DAX 40 | 22,328.77 | 292.18 | -1.29% |
| Dow JONES (US) | 41,433.48 | 478.23 | -1.14% |
| FTSE 100 | 8,495.99 | 104.23 | -1.21% |
| HKSE | 23,623.55 | 158.59 | -0.67% |
| NASDAQ | 17,436.10 | 32.22 | -0.18% |
| Nikkei 225 | 36,850.83 | 57.72 | 0.16% |
| NZX 50 Index | 12,249.55 | 161.42 | -1.30% |
| S&P 500 | 5,572.07 | 42.49 | -0.76% |
| S&P/ASX 200 | 7,756.90 | 133.20 | -1.69% |
| SSE Composite Index | 3,375.17 | 4.66 | -0.14% |